BBIO peer analysis
BridgeBio Pharma (BBIO) against its competitors: price, today's move, 1-year return and market value side by side.
BBIO and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALNY Alnylam | $161.09 | -2.37% | -64.17% | $22.10B |
| ASND Ascendis Pharma | $251.12 | -0.06% | 23.28% | $16.53B |
| BMRN BioMarin | $58.17 | -0.58% | 12.06% | $11.33B |
| DNLI Denali Therapeutics | $18.77 | -0.90% | 14.59% | $3.03B |
| IONS Ionis Pharmaceuticals | $41.88 | -3.76% | -43.53% | $7.23B |
| MAZE Maze Therapeutics | $30.09 | -4.42% | -9.42% | – |
| PTCT PTC Therapeutics | $60.82 | 1.42% | -10.70% | $5.01B |
| RARE Ultragenyx | $16.10 | 0.00% | -54.22% | $1.59B |
| SRRK Scholar Rock | $43.30 | -1.37% | 47.43% | $5.35B |
| TVTX Travere Therapeutics | $49.51 | -1.75% | 66.98% | – |
| BBIO BridgeBio Pharma | $75.72 | 1.03% | 19.49% | $14.60B |
- BBIO's peers: ALNY (Alnylam), ASND (Ascendis Pharma), BMRN (BioMarin), DNLI (Denali Therapeutics), IONS (Ionis Pharmaceuticals), MAZE (Maze Therapeutics), PTCT (PTC Therapeutics), RARE (Ultragenyx).
Updated 2026-11-02 17:55 UTC